9 September 2024
Latham & Watkins Advises Ascendis Pharma in US$150 Million Royalty Financing
Advising firms
Deal team
14 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Dan Van Fleet Lead | Latham & Watkins LLP | Partner | transactional | Not stated |
| Mark Roeder Lead | Latham & Watkins LLP | Partner | transactional | Not stated |
| John Williams Lead | Latham & Watkins LLP | Partner | transactional | Not stated |
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | transactional | Not stated |
| Erin Cusenbary | Latham & Watkins LLP | Associate | transactional | Not stated |
| Tyler Israel | Latham & Watkins LLP | Associate | transactional | Not stated |
| Ryleigh Chen | Latham & Watkins LLP | Associate | transactional | Not stated |
| Jekkie Kim | Latham & Watkins LLP | Partner | intellectual property | Not stated |
| Mizuna Sekine | Latham & Watkins LLP | Associate | intellectual property | Not stated |
| Patrick Chew | Latham & Watkins LLP | Associate | intellectual property | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax | Not stated |
| Sam Yang | Latham & Watkins LLP | Associate | tax | Not stated |
| Ben Haas | Latham & Watkins LLP | Partner | FDA regulatory | Not stated |
| Monica Groat | Latham & Watkins LLP | Counsel | FDA regulatory | Not stated |
11 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 150m (US$150 million)
- What the figure measures
- Facility amount
- Client
- Ascendis PharmaBorrower
- Counterparties
- Royalty Pharma (Lenders)